309 related articles for article (PubMed ID: 37594487)
41. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F
Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
[TBL] [Abstract][Full Text] [Related]
42. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
Lau KH; Kumar A; Yang IH; Nowak RJ
Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
[TBL] [Abstract][Full Text] [Related]
43. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract][Full Text] [Related]
44. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
45. Case Report and Review of 7 Similar Cases in the Literature: Cutaneous Sarcoidosis as Side Effect of Pembrolizumab Plus Chemotherapy in Stage IV Squamous Cell Carcinoma of Lung.
Trilleras-Gomez AP; Hull KJ; Drew DZ
J Immunother; 2021 Feb-Mar 01; 44(2):90-94. PubMed ID: 33298795
[TBL] [Abstract][Full Text] [Related]
46. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
47. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
48. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
Trinidad C; Nelson KC; Glitza Oliva IC; Torres-Cabala CA; Nagarajan P; Tetzlaff MT; Ivan D; Hwu WJ; Prieto VG; Curry JL; Aung PP
J Cutan Pathol; 2018 Jul; 45(7):504-507. PubMed ID: 29633300
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
50. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
[TBL] [Abstract][Full Text] [Related]
51. Non-bacterial cystitis secondary to pembrolizumab: A case report and review of the literature.
He X; Tu R; Zeng S; He Z; Liu S; Fang Y
Curr Probl Cancer; 2022 Aug; 46(4):100863. PubMed ID: 35687965
[TBL] [Abstract][Full Text] [Related]
52. Hypothyroid ataxia complicating monoclonal antibody therapy.
Badran A; Moran C; Coles AJ
Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
[TBL] [Abstract][Full Text] [Related]
53. Neurological adverse effects due to programmed death 1 (PD-1) inhibitors.
Shi S; Jaoube JA; Kanwar R; Jin MC; Amorin A; Varanasi V; Eisinger E; Thomas R; Moore JM
J Neurooncol; 2020 Jun; 148(2):291-297. PubMed ID: 32350779
[TBL] [Abstract][Full Text] [Related]
54. A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report.
Hamada K; Yoshimura K; Oshinomi K; Hirasawa Y; Ariizumi H; Ohkuma R; Shida M; Kubota Y; Matsui H; Ishiguro T; Sambe T; Ishida H; Horiike A; Wada S; Iwamoto S; Uchida N; Ogawa Y; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2022 Jan; 101(2):e28339. PubMed ID: 35029177
[TBL] [Abstract][Full Text] [Related]
55. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
56. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
57. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
[TBL] [Abstract][Full Text] [Related]
58. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
59. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
60. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Läubli H; Balmelli C; Bossard M; Pfister O; Glatz K; Zippelius A
J Immunother Cancer; 2015; 3():11. PubMed ID: 25901283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
